Hemispherx Biopharma Inc. (HEB)

1.80
AMEX : Health Technology
Prev Close 1.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.69 / 14.81
Avg Volume 582.80K
Exchange AMEX
Shares Outstanding 2.44M
Market Cap 4.40M
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care For Alferon N Injection(R)

Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care For Alferon N Injection(R)

Two-Year Extension Follows Completion of $8 Million Upgrade and Preparation for Re-Launch of Alferon N in the US

Hemispherx Biopharma Announces Financial Results For The Six Months Ended June 30, 2015

Hemispherx Biopharma Announces Financial Results For The Six Months Ended June 30, 2015

New Program Launched in Concert With Facilities Enhancement

Hemispherx Biopharma Board Appoints New President

Hemispherx Biopharma Board Appoints New President

Seasoned Executive With Extensive International Experience

Hemispherx Expands Its Collaboration With Emerge Health For The Commercialization Of Alferon In Australia And New Zealand

Hemispherx Expands Its Collaboration With Emerge Health For The Commercialization Of Alferon In Australia And New Zealand

Hemispherx and Emerge Health to Commence a Named Patient Program While Seeking Formal Regulatory Approval

Hemispherx To Present At The Marcum Microcap Conference In New York

Hemispherx To Present At The Marcum Microcap Conference In New York

Planned Launch of Alferon N Injection(R) Highlighted

Hemispherx Biopharma Announces Financial Results For The Three Months Ended March 31, 2015

Hemispherx Biopharma Announces Financial Results For The Three Months Ended March 31, 2015

Newly Upgraded Alferon Facility Completed; Production of New Alferon API Inventory Commenced in February 2015; Our European Subsidiary Received Formal Notification of Approval of Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

4 Stocks Under $10 Making Big Moves Higher

4 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Insider Trading Alert - NDAQ, FEYE And HEB Traded By Insiders

Insider Trading Alert - NDAQ, FEYE And HEB Traded By Insiders

Stocks with insider trader activity include NDAQ, FEYE and HEB

Insider Trading Alert - KCG, HEB And OXM Traded By Insiders

Insider Trading Alert - KCG, HEB And OXM Traded By Insiders

Stocks with insider trader activity include KCG, HEB and OXM

Insider Trading Alert - HEB, MS And IMPV Traded By Insiders

Insider Trading Alert - HEB, MS And IMPV Traded By Insiders

Stocks with insider trader activity include HEB, MS and IMPV

Insider Trading Alert - FTD, HEB And AWH Traded By Insiders

Insider Trading Alert - FTD, HEB And AWH Traded By Insiders

Stocks with insider trader activity include FTD, HEB and AWH

Hemispherx Biopharma To Present Data On The Activity Of Ampligen(R) Against The Ebola Virus

Hemispherx Biopharma To Present Data On The Activity Of Ampligen(R) Against The Ebola Virus

In Vivo Data at 7th International Symposium on Filoviruses, March 25-March 28, 2015 in Washington, DC

Hemispherx Biopharma Announces Financial Results For The Year Ended December 31, 2014

Hemispherx Biopharma Announces Financial Results For The Year Ended December 31, 2014

Newly Upgraded Alferon(R) Facility Completed; Production of New Alferon(R) API Inventory Commenced in February 2015

Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses

Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses

Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.

Hemispherx Enters A Collaboration With Emerge Health For The Commercialization Of Ampligen For Chronic Fatigue Syndrome (CFS) In Australia And New Zealand

Hemispherx Enters A Collaboration With Emerge Health For The Commercialization Of Ampligen For Chronic Fatigue Syndrome (CFS) In Australia And New Zealand

Hemispherx and Emerge Health to Commence Named Patient Sales While Seeking Formal Regulatory Approval

Regulators Want Drug Companies to Be Honest About FDA

Regulators Want Drug Companies to Be Honest About FDA

The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.